In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells
Molecular Therapy · 2026-10 · 34 (10) · 5783-5795
DOI: 10.1016/j.ymthe.2026.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Travis J Friesen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Umoja Biopharma, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 2, Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ex vivo-manufactured chimeric antigen receptor (CAR) T cells targeting CD19 have transformed treatment strategies for patients with B cell malignancies and have shown promising results in autoimmune disease. Yet despite their success, significant barriers remain that impede patient access to these therapies, including their complex manufacturing and the need for lymphodepleting chemotherapy. Moreover, many patients who receive ex vivo-manufactured CD19 CAR T cells do not achieve durable responses, suggesting that the expansion and persistence of CAR T cells may need improvement, and/or that strategies targeting alternative antigens may be needed for patients who are refractory to or relapse following treatment with CD19-directed therapies. Umoja is developing a surface-engineered lentiviral vector platform capable of generating CAR T cells in vivo without lymphodepletion. UB-VV400 delivers a payload composed of a fully human anti-CD22 CAR and the rapamycin-activated cytokine receptor (RACR), which enable preferential expansion and enrichment of CAR T cells in response to rapamycin. Here, we describe preclinical studies demonstrating that UB-VV400 generates anti-CD22 CAR T cells that kill CD22-expressing B cells and tumor cells in vitro and in vivo, and that engagement of RACR results in the selective expansion and enrichment of CAR T cells in vivo leading to complete tumor clearance and B cell depletion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Umoja Biopharma, Seattle, WA 98109, USA.
- Umoja Biopharma, Louisville, CO 80027, USA.
- Umoja Biopharma, Seattle, WA 98109, USA. Electronic address: jeff.teoh@umoja-biopharma.com.
Zitieren
APA
Friesen, T. J., Sheih, A., Perdue, N., Ericson, N. G., Jarrell, D., Yingst, A. M., Nicolai, C. J., Gervascio, T., Shin, S., Freeman, J., Beitz, L. O., O'Hara, S. D., Sullivan, A. M., Brandes, A. H., Larson, R. P., & Teoh, J. J. (2026). In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells. Molecular Therapy, 34(10), 5783-5795. https://doi.org/10.1016/j.ymthe.2026.08.003
Vancouver
Friesen TJ, Sheih A, Perdue N, Ericson NG, Jarrell D, Yingst AM, et al. In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells. Molecular Therapy. 2026;34(10):5783-5795. doi:10.1016/j.ymthe.2026.08.003
BibTeX
@article{Friesen2026,
author = {Friesen, Travis J and Sheih, Alyssa and Perdue, Nikole and Ericson, Nolan G and Jarrell, Dillon and Yingst, Ashley M and Nicolai, Christopher J and Gervascio, Timothy and Shin, Seungjin and Freeman, Jessica and Beitz, Laurie O and O'Hara, Samantha D and Sullivan, Alessandra M and Brandes, Alissa H and Larson, Ryan P and Teoh, Jeffrey J},
title = {In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {10},
pages = {5783--5795},
doi = {10.1016/j.ymthe.2026.08.003}
}
EUVIMED